<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00713921</url>
  </required_header>
  <id_info>
    <org_study_id>051008</org_study_id>
    <nct_id>NCT00713921</nct_id>
  </id_info>
  <brief_title>Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients</brief_title>
  <official_title>Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Thomas Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke. Develop pilot data of medical therapy (Detrol LA) in diabetic and stroke bladder dysfunction.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Bladder Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detrol LA</intervention_name>
    <description>Oral Detrol LA, 4mg daily for sim months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Stroke Population:

          -  Ischemic or hemorrhagic stroke in the anterior or posterior circulation within the
             past month in persons 21 years of age and over

          -  NIH Stroke Scale Score of 4 or greater one month post-stroke

          -  Modified Rankin Scale of 2 or greater

          -  Patients with motor or verbal impairment with surrogacy consent

        Inclusion Criteria:

        Diabetic Population:

          -  Clinically stable diabetes type 2 females 21 years of age or older

          -  Peripheral neuropathy associated with diabetes Dyck stage 2 or 3

          -  Clinical evaluation by neurologist reveals no other likely cause of neuropathy

        Exclusion Criteria:

        Stroke Population:

          -  Men

          -  Patients with cardiac pacemaker or other indwelling device that would preclude
             neurophysiologic testing;

          -  Patients with an indwelling urinary catheter that cannot be removed

          -  Patients who are on warfarin or similar anticoagulants that cannot be stopped for the
             study procedures

          -  Patients with a poor prognosis due to stroke or underlying illness who, it is
             anticipated, would be unable to participate for the period of the study

          -  Females with current pregnancy, multiparity &gt;/=4, prior pelvic floor dysfunction, or
             pelvic floor tumor. Women with incontinence prior to stroke, cystocele, rectocele, or
             urethral stricture

          -  Patients unable to tolerate Detrol LA; such patients would include those with
             significant renal or hepatic disease, those currently taking drugs metabolized by the
             cytochrome P450 enzyme system that might confound interpretation of responses (
             Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine,
             ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine,
             grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin,
             verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin,
             St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with
             urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those
             with a known sensitivity to the drug or its ingredients

          -  Patients who have a history of diabetes

          -  Pregnancy or actively seeking pregnancy

          -  Patients who are cognitively impaired

        Diabetes Population:

        Exclusion Criteria:

          -  Men

          -  Patients with cardiac pacemaker or other indwelling device that would preclude
             neurophysiologic testing;

          -  Patients with an indwelling urinary catheter that cannot be removed

          -  Patients who are on warfarin or similar anticoagulants that cannot be stopped for the
             study procedures

          -  Patients with a poor prognosis due to underlying illness who, it is anticipated, would
             be unable to participate for the period of the study

          -  Females with current pregnancy, multiparity &gt;/=4, prior pelvic floor dysfunction,
             pelvic floor tumor, cystocele, rectocele, or urethral stricture

          -  Patients unable to tolerate Detrol LA; such patients would include those with
             significant renal or hepatic disease, those currently taking drugs metabolized by the
             cytochrome P450 enzyme system that might confound interpretation of responses (
             Delaviridine, indinavir, nelfinavir, ritonavir, amiodarone, aprepitant, cimetidine,
             ciprofloxacin, clarithromycin, diltiazem, erythromycin, fluconazole, fluvoxamine,
             grapefruit juice, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacin,
             verapamil, efavirenz, nevirapine, carbamazepine, phenobarbital, phenyltoin, rifampin,
             St. John's wort, troglitazone, oxcarbazepine, pioglitazone, rifabutin); those with
             urinary retention, gastric retention, uncontrolled narrow angel glaucoma, or those
             with a known sensitivity to the drug or its ingredients

          -  Pregnancy or actively seeking pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry K Jarnagin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barry K Jarnagin, MD</last_name>
    <phone>615-771-7580</phone>
    <email>barry.jarnagin@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt Univiersity</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Black</last_name>
      <phone>615-343-9933</phone>
    </contact>
    <investigator>
      <last_name>Barry Jarnagin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Diabetics</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholinergic Antagonists</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

